Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.
Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M. Bermejo M, et al. Among authors: climent n. Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. Epub 2018 Aug 22. Biochem Pharmacol. 2018. PMID: 30142322
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M. Vigón L, et al. Among authors: climent n. Biochem Pharmacol. 2020 Dec;182:114203. doi: 10.1016/j.bcp.2020.114203. Epub 2020 Aug 20. Biochem Pharmacol. 2020. PMID: 32828803 Free PMC article.
Immunological and virological findings in a patient with exceptional post-treatment control: a case report.
Climent N, Ambrosioni J, González T, Xufré C, Casadellà M, Noguera-Julian M, Paredes R, Plana M, Grau-Expósito J, Mallolas J, Alcamí J, Sánchez-Palomino S, Miró JM; Hospital Clínic de Barcelona PHI investigators. Climent N, et al. Lancet HIV. 2023 Jan;10(1):e42-e51. doi: 10.1016/S2352-3018(22)00302-2. Epub 2022 Oct 27. Lancet HIV. 2023. PMID: 36354046
Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.
Bermejo M, López-Huertas MR, García-Pérez J, Climent N, Descours B, Ambrosioni J, Mateos E, Rodríguez-Mora S, Rus-Bercial L, Benkirane M, Miró JM, Plana M, Alcamí J, Coiras M. Bermejo M, et al. Among authors: climent n. Biochem Pharmacol. 2016 Apr 15;106:30-45. doi: 10.1016/j.bcp.2016.02.002. Epub 2016 Feb 4. Biochem Pharmacol. 2016. PMID: 26851491
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group. Mothe B, et al. Among authors: climent n. J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25724985 Clinical Trial.
A therapeutic dendritic cell-based vaccine for HIV-1 infection.
García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. García F, et al. Among authors: climent n. J Infect Dis. 2011 Feb 15;203(4):473-8. doi: 10.1093/infdis/jiq077. Epub 2011 Jan 13. J Infect Dis. 2011. PMID: 21233310 Free PMC article. Clinical Trial.
Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.
Leal L, Guardo AC, Bedoya LM, Rodríguez de Miguel C, Climent N, Rovira C, Beltrán M, Llach J, Alcamí J, Kashuba ADM, Gatell JM, Plana M, García F. Leal L, et al. Among authors: climent n. AIDS Res Hum Retroviruses. 2023 May;39(5):211-221. doi: 10.1089/AID.2021.0232. Epub 2023 Feb 15. AIDS Res Hum Retroviruses. 2023. PMID: 36416229
58 results